SGOT (1.9%), increased SGPT (1.8%), cholestatic jaundice (1.1%), bilirubinemia (0.8%), and jaundice (0.2%). Serious and sometimes fatal cases of clinical hepatitis , cholestasis , and fulminant hepatic failure have rarely been reported. Additional possible side effects reported in less than 1% of patients have included increases in creatine phosphokinase , and GGT /LDH,